covid heroes

University of Houston partners with health system to provide COVID-19 protective equipment

Aaron McEuen of the University of Houston's Gerald D. Hines College of Architecture and Design answered the call for creating medical face shields for Harris Health System. Photo via uh.edu

A Houston health system was in need of protective personal equipment, or PPE, when they reached out to a local academic institution for support.

Harris Health System tapped the University of Houston to make medical face shields for doctors and nurses at the system's two hospitals — Ben Taub and Lyndon B. Johnson.

"Face shields are one of our most challenging pieces of protective equipment to get during these times of need," says Chris Okezie, vice president of system operations at Harris Health System, in a news release. "They're also the most effective equipment to protect our front-line staff."

One college on campus is particularly equipped to build things, and that's the Gerald D. Hines College of Architecture and Design — specifically the college's Burdette Keeland Jr. Design Exploration Center. It took only a day for the center to build a prototype. Harris Health then made an initial order of 500 masks.

The lab uses universal laser cutters to create the semi-circle of plastic for the shield — the machines can cut 10 pieces in less than 3 minutes. Then, it can be assembled manually. Aaron McEuen, instructional lab manager at the center, is leading the efforts.

"Honestly, it's nice to be productive. I know a lot of people are cooped up in their houses," he says. "We're lucky to have the opportunity to contribute."

One challenge McEuen is facing is procuring the raw materials for the shields. as shipping and delivery times are slower during the pandemic. Despite the obstacles, Harris Health System's president and CEO, Dr. Esmaeil Porsa, is grateful for the support and effort.

"This is a great example of how people of this great city and county come together to address a common and dire need," says Porsa in the release. "I want to personally thank the staff and leadership of University of Houston for stepping up and leading the way to help Harris Health care for our communities in the safest possible way."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted